CNBC April 9, 2024
Annika Kim Constantino, Ashley Capoot

Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday.

But J&J’s drug is walking away with a notable edge over its rival.

The FDA expanded the approvals of both therapies, allowing patients to use them as earlier lines of treatment for a type of blood cancer called multiple myeloma. That can damage the bones, immune system, kidneys and red blood cell count.

Before that decision, J&J’s drug Carvykti and Bristol Myers’s treatment Abecma were both only available to people who previously received at least four specific drug regimens for the incurable blood cancer.

First and foremost, the expanded approvals are a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
STAT+: How Trump’s tariffs may raise health care costs, from medical devices to prescription drugs
One Institution’s Evidence-Based Approach to Adopting Biosimilars
Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries

Share This Article